William Love
Founder bij DESTINY PHARMA PLC
Vermogen: 2 M $ op 31-03-2024
Profiel
William Guy Love is the founder of Destiny Pharma Plc, a company founded in 1996.
He currently holds the title of Chief Scientific Officer & Executive Director at Destiny Pharma Plc.
In addition to his founding position, Dr. Love also held a former job as a Founding Member at Beam Alliance.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
DESTINY PHARMA PLC
6.83% | 18-10-2023 | 6 509 500 ( 6.83% ) | 2 M $ | 31-03-2024 |
Actieve functies van William Love
| Bedrijven | Functie | Begin |
|---|---|---|
| DESTINY PHARMA PLC | Founder | 04-03-1996 |
Eerdere bekende functies van William Love
| Bedrijven | Functie | Einde |
|---|---|---|
Beam Alliance
 Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| DESTINY PHARMA PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Beam Alliance
Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Health Technology |
